Methods and apparatus for modeling cancer metastasis in vitro

Patent metadata

Field	Value
Publication number	US-11047847-B2
Application number	US-201615765085-A
Country	US
Kind code	B2
Filing date	Sep 30, 2016
Priority date	Oct 2, 2015
Publication date	Jun 29, 2021
Grant date	Jun 29, 2021

Abstract

An apparatus useful for examining metastasis of cancer cells, includes (a) a primary chamber; (b) at least one secondary chamber; (c) at least one primary conduit connecting said primary and secondary chambers and providing fluid communication therebetween; (d) a primary organoid in said first chamber, said primary organoid comprising mammalian cancer cells; (e) at least one secondary organoid separately selected for and in said secondary chamber(s); and (f) optionally a growth media in said primary chamber, each of said secondary chamber(s), and said primary conduit. The apparatus may be used in methods of drug screening and development, and in personalized medicine.

First claim

That which is claimed is:

1. An apparatus comprising: a primary chamber including a first organoid that comprises mammalian cancer cells and a first hydrogel, wherein the first organoid is present within the first hydrogel;
at least one secondary chamber, wherein the at least one secondary chamber comprises a second organoid and a second hydrogel, wherein the second organoid is present within the second hydrogel;
at least one primary conduit connecting said primary and secondary chambers and providing fluid communication therebetween;
a fluid circuit that, in operation, is a closed fluidic system and provides fluid flow through the primary chamber and first organoid, then through the at least one primary conduit, next through at least one branching conduit that branches off of the at least one primary conduit, and then to the at least one secondary chamber and second organoid in the same fluid path, wherein the circuit comprises the at least one primary conduit connecting said primary and secondary chambers and providing fluid communication therebetween; and
a growth media in said primary chamber, each of said secondary chamber(s), and each of said primary conduit(s), wherein said first and second hydrogels comprise thiolated hyaluronic acid, thiolated gelatin, and polyethylene glycol diacrylate.

2. The apparatus of claim 1 , wherein said first organoid further comprises:
mammalian tissue cells, optionally in an extracellular matrix; or
an extracellular matrix carrying said cancer cells;
optionally, a layer of blood vessel or lymphatic endothelial cells at least partially around or above said first organoid; and
optionally, immune system cells.

3. The apparatus of claim 1 , further comprising an optically transparent window in said primary and/or secondary chambers.

4. The apparatus of claim 1 , wherein said first organoid comprises a layer of blood vessel or lymphatic endothelial cells at least partially around or above said first organoid.

5. The apparatus of claim 1 , further comprising a fluid inlet connected to said primary chamber and a fluid outlet connected to each of said secondary chamber(s).

6. The apparatus of claim 1 , wherein said secondary chambers are connected to one another in series, in parallel, or in combinations thereof.

7. The apparatus of claim 1 , wherein said cancer cells express a detectable compound.

8. The apparatus of claim 1 , wherein the second organoid comprises a lung, lymph node, liver, bone, central nerve, skin, smooth muscle, or skeletal muscle organoid.

9. The apparatus of claim 1 , wherein:
said first organoid comprises intestinal epithelial cells in combination with colon carcinoma cells, and said second organoid comprises a liver, central nerve, peripheral nerve, or bone organoid;
said first organoid comprises lung airway epithelial cells in combination with either small cell lung cancer or lung adenocarcinoma cells, and said second organoid comprises a peripheral nerve, central nerve, liver, or bone organoid;
said first organoid comprises mammary gland epithelial cells in combination with breast carcinoma, adenocarcinoma or sarcoma cells, and said second organoid comprises a liver, peripheral nerve, central nerve, bone, lung, lymph node, smooth muscle, skeletal muscle, or skin organoid;
said first organoid comprises prostate gland cells in combination with prostate acinar or ductal adenocarcinoma cells, and said second organoid comprises a liver, peripheral nerve, central nerve, bone, lung, or lymph node organoid; or
said first organoid comprises keratinocytes, optionally melanocytes, and melanoma cells in combination, and said second organoid comprises a liver, peripheral nerve, central nerve, bone, lung, skin or lymph node organoid;
said first organoid comprises central nervous system tumor cells optionally differentiated central nervous system cells and said second organoid comprises a central nerve organoid;
said first organoid comprises liver cells in combination with hepatoma or hepatocellular carcinoma cells, and said second organoid comprises a peripheral nerve, central nerve, lymph node, lung, or bone organoid;
said first organoid comprises pancreatic cells in combination with pancreatic adenocarcinoma cells, and said second organoid comprises a peripheral nerve, central nerve, lymph node, liver, lung, or bone organoid;
the first organoid comprises endometrial cells, and optionally myometrial cells, in combination with endometrial carcinoma, uterine sarcoma, or uterine carcinosarcoma cells, and the second organoid comprises a lung, lymph node, liver, bone, central nerve, skin, smooth muscle, or skeletal muscle organoid; or
the first organoid comprises cervical mucosa cells and optionally smooth muscle cells in combination with cervical squamous carcinoma or adenocarcinoma cells, and the second organoid comprises bladder, bone, lung, liver, smooth muscle, skeletal muscle, or intestinal organoid.

10. The apparatus of claim 1 , further comprising a pump operatively associated with said primary chamber for circulating said growth media from said primary chamber to said at least one secondary chamber.

11. The apparatus of claim 1 , further comprising a growth media reservoir and/or bubble trap operatively associated with said primary chamber.

12. The apparatus of claim 1 , further comprising a return conduit operatively associated with said primary and secondary chambers for returning growth media circulated through said at least one secondary chamber to said primary chamber.

13. The apparatus of claim 1 , packaged in a container together with a cooling element in said container.

14. The apparatus of claim 1 , further comprising a first planar member and a second planar member, wherein the first organoid and the second organoid are each between the first planar member and the second planar member.

15. An apparatus of claim 1 wherein said thiolated hyaluronic add, said thiolated gelatin, and said polyethylene glycol diacrylate are cross-linked.

16. A method of screening a test compound for anti-metastatic activity against cancer cells, comprising the steps of:
providing the apparatus of claim 1 ;
circulating the growth medium from said primary chamber to said at least one secondary chamber;
administering a test compound to said first organoid; and
determining a decrease in the presence of cancer cells in said second organoid, as compared to the number of cancer cells present in said second organoid when said test compound is not administered.

17. The method of claim 16 , wherein said cancer cells express a detectable compound, said at least one secondary chamber has an optically transparent window, and said determining step is carried out by detecting said detectable compound through said window.

18. The method of claim 16 , wherein said determining step is carried out a plurality of times sequentially spaced from one another.

19. A method of screening a test compound for anti-cancer or anti-metastatic activity against cancer cells in a subject, comprising the steps of:
providing the apparatus of claim 1 , wherein said mammalian cancer cells are isolated from said subject;
circulating the growth medium from said primary chamber to said at least one secondary chamber;
administering a test compound to said first organoid; and
determining a decrease in the presence of cancer cells in said first organoid and/or said at least one second organoid, as compared to the number of cancer cells present in said first organoid and/or said at least one second organoid when said t

Assignees

• Univ Wake Forest Health Sciences

Inventors

• Skardal Aleksander

Classifications

• G01N33/5011 Primary

  for testing antineoplastic activity · CPC title

• B01L2200/10

  Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept · CPC title

• B01L3/502761 Primary

  specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules · CPC title

• C12M21/08

  for producing artificial tissue or for ex-vivo cultivation of tissue (prostheses A61F2/00, grafts A61L27/00) · CPC title

• C12M27/18

  Flow directing inserts · CPC title